These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 32378579)
21. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Al-Mawali A; Gillis D; Lewis I Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561 [TBL] [Abstract][Full Text] [Related]
22. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. Czyz A; Nagler A Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875 [TBL] [Abstract][Full Text] [Related]
24. The emerging role of measurable residual disease detection in AML in morphologic remission. Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088 [TBL] [Abstract][Full Text] [Related]
25. Minimal Residual Disease in Acute Myeloid Leukemia. Gomez-Arteaga A; Guzman ML Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263 [TBL] [Abstract][Full Text] [Related]
26. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Al-Mawali A; Gillis D; Lewis I Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068 [TBL] [Abstract][Full Text] [Related]
27. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332 [TBL] [Abstract][Full Text] [Related]
28. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis]. Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028 [TBL] [Abstract][Full Text] [Related]
29. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. Wood BL Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834 [TBL] [Abstract][Full Text] [Related]
30. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia]. Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362 [TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765 [TBL] [Abstract][Full Text] [Related]
32. Should minimal residual disease guide therapy in AML? Paietta E Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765 [TBL] [Abstract][Full Text] [Related]
33. MRD in AML: does it already guide therapy decision-making? Ossenkoppele G; Schuurhuis GJ Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):356-365. PubMed ID: 27913502 [TBL] [Abstract][Full Text] [Related]
34. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia. Zelezníková T; Babusíková O Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719 [TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease in acute myeloid leukemia: coming of age. Paietta E Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558 [TBL] [Abstract][Full Text] [Related]
37. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]. Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899 [TBL] [Abstract][Full Text] [Related]
38. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313 [TBL] [Abstract][Full Text] [Related]
39. Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry. Li W; Morgan R; Nieder R; Truong S; Habeebu SSM; Ahmed AA Cytometry B Clin Cytom; 2021 Sep; 100(5):590-601. PubMed ID: 33197125 [TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Vidriales MB; Pérez-López E; Pegenaute C; Castellanos M; Pérez JJ; Chandía M; Díaz-Mediavilla J; Rayón C; de Las Heras N; Fernández-Abellán P; Cabezudo M; de Coca AG; Alonso JM; Olivier C; Hernández-Rivas JM; Montesinos P; Fernández R; García-Suárez J; García M; Sayas MJ; Paiva B; González M; Orfao A; San Miguel JF; Leuk Res; 2016 Jan; 40():1-9. PubMed ID: 26598032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]